Inovio Pharmaceuticals (NASDAQ:INO) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research note issued to investors on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Inovio Pharmaceuticals Stock Down 2.1 %

Shares of Inovio Pharmaceuticals stock opened at $0.42 on Friday. The stock’s 50-day simple moving average is $0.41 and its 200-day simple moving average is $0.49. Inovio Pharmaceuticals has a 52 week low of $0.32 and a 52 week high of $2.17. The company has a market capitalization of $114.66 million, a price-to-earnings ratio of -0.65 and a beta of 0.98.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several large investors have recently added to or reduced their stakes in INO. MetLife Investment Management LLC lifted its holdings in Inovio Pharmaceuticals by 56.5% during the 1st quarter. MetLife Investment Management LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $411,000 after buying an additional 41,285 shares in the last quarter. Vanguard Group Inc. grew its stake in Inovio Pharmaceuticals by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 11,247,922 shares of the biopharmaceutical company’s stock worth $40,381,000 after acquiring an additional 208,609 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Inovio Pharmaceuticals by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,530,604 shares of the biopharmaceutical company’s stock worth $5,495,000 after acquiring an additional 54,889 shares in the last quarter. Renaissance Technologies LLC bought a new position in Inovio Pharmaceuticals in the 1st quarter worth about $1,414,000. Finally, Hsbc Holdings PLC grew its stake in Inovio Pharmaceuticals by 15.7% in the 1st quarter. Hsbc Holdings PLC now owns 47,672 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 6,475 shares in the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.